However, the aberrant activation of DR6 has been widely reported in the development and progression of different pathophysiological conditions, including rheumatoid arthritis, inflammatory bowel disease, Alzheimer's disease, type 2 diabetes, and cancers (Ren et al. 2022). The gene discussed is TNFRSF21; the disease is cancer.